{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gonsalves WI"],"funding":["Mayo Clinic","National Cancer Institute","NCI NIH HHS"],"pagination":["310-315"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7724649"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["95(3)"],"pubmed_abstract":["Our prior studies identified the prognostic significance of quantifying cPCs by multiparametric flow cytometry (MFC) in newly diagnosed multiple myeloma (NDMM) patients. We evaluated if a similar quantification of cPCs could add prognostic value to the current R-ISS classification of 556 consecutive NDMM patients seen at the Mayo Clinic, Rochester from 2009 to 2017. Those patients that had ≥5 cPCs/μL and either R-ISS stage I or stage II disease were re-classified as R-ISS IIB stage for the purposes of this study. The median time to next therapy (TTNT) and overall survival (OS) for patients with ≥5 cPCs/μL at diagnosis was as follows: R-ISS I (N = 110) - 40 months and not reached; R-ISS II (N = 69) - 30 and 72 months; R-ISS IIB (N = 96) - 21 and 45 months and R-ISS III (N = 281) - 20 and 47 months respectively. Finally, ≥ 5 cPCs/μL retained its adverse prognostic significance in a multivariable model for TTNT and OS. Hence, quantifying cPCs by MFC can potentially enhance the R-ISS classification of a subset of NDMM patients with stage I and II disease by identifying those patients with a worse than expected survival outcome."],"journal":["American journal of hematology"],"pubmed_title":["Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells."],"pmcid":["PMC7724649"],"funding_grant_id":["K23 CA218742","P50CA186781","P50 CA186781","K23CA218742"],"pubmed_authors":["Warsame R","Go RS","Lust JA","Rajkumar SV","Hayman SR","Lin Y","Gonsalves WI","Buadi FK","Dispenzieri A","Gertz MA","Lacy MQ","Kumar SK","Siddiqui MA","Hobbs M","Fonder A","Kyle RA","Kapoor P","Nandakumar B","Muchtar E","Dingli D","Kourelis TV","Leung N","Russell S","Hwa YL","Jevremovic D"],"additional_accession":[]},"is_claimable":false,"name":"Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.","description":"Our prior studies identified the prognostic significance of quantifying cPCs by multiparametric flow cytometry (MFC) in newly diagnosed multiple myeloma (NDMM) patients. We evaluated if a similar quantification of cPCs could add prognostic value to the current R-ISS classification of 556 consecutive NDMM patients seen at the Mayo Clinic, Rochester from 2009 to 2017. Those patients that had ≥5 cPCs/μL and either R-ISS stage I or stage II disease were re-classified as R-ISS IIB stage for the purposes of this study. The median time to next therapy (TTNT) and overall survival (OS) for patients with ≥5 cPCs/μL at diagnosis was as follows: R-ISS I (N = 110) - 40 months and not reached; R-ISS II (N = 69) - 30 and 72 months; R-ISS IIB (N = 96) - 21 and 45 months and R-ISS III (N = 281) - 20 and 47 months respectively. Finally, ≥ 5 cPCs/μL retained its adverse prognostic significance in a multivariable model for TTNT and OS. Hence, quantifying cPCs by MFC can potentially enhance the R-ISS classification of a subset of NDMM patients with stage I and II disease by identifying those patients with a worse than expected survival outcome.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2024-10-15T10:20:44.551Z","creation":"2021-02-20T07:37:16Z"},"accession":"S-EPMC7724649","cross_references":{"pubmed":["31867775"],"doi":["10.1002/ajh.25709"]}}